Recorded Urinary Ketone Results After Initiation of SGLT2 Inhibitors in Patients With and Without Diabetes: A Single-Center Retrospective Descriptive Study

Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are prescribed for diabetes, chronic heart failure, and chronic kidney disease but are rarely associated with ketoacidosis, including euglycemic ketoacidosis. Although ketonuria is nonspecific and is not diagnostic of ketoacidosis, a positive urinary ketone result may prompt further clinical assessment. This study compared the proportion of participants with a recorded urinary ketone result after SGLT2i initiation between those with and without diabetes. Methods: This retrospective, single-center descriptive study included adults who initiated SGLT2i therapy at the study hospital between April 2022 and March 2023 and continued treatment for at least 180 days. Urinary ketone results, semiquantitative grades, and selected gastrointestinal symptoms documented in the electronic health record were assessed. Results: Among 465 participants, a urinary ketone result was recorded in 273 of 350 participants in the diabetes group (78.0%) and 65 of 115 participants in the non-diabetes group (56.5%) (odds ratio, 2.73; 95% confidence interval, 1.74-4.26). During follow-up, 27 participants had a positive urinary ketone result; the highest recorded grade was 2+ or higher in 17 (63.0%). Among 127 participants without a recorded urinary ketone result, selected gastrointestinal symptoms were documented in 11 (8.7%), and no blood ketone result was identified for these participants. No documented hospital admissions for ketoacidosis were identified in the study hospital records. Conclusions: The proportion of participants with a recorded urinary ketone result after SGLT2i initiation was lower in the non-diabetes group than in the diabetes group. Although urinary ketone positivity alone cannot confirm ketoacidosis, a positive semiquantitative result may prompt context-based clinical review and, when clinically indicated, confirmatory evaluation. These findings suggest the importance of maintaining awareness of SGLT2i-associated ketoacidosis, including euglycemic ketoacidosis, regardless of diabetes status, and a potential role for pharmacists in facilitating context-based ketone assessment when clinically indicated.

Authors

Institutions

Publication Details

Journal
Hospital Pharmacy
Published
2026-11-21
DOI
https://doi.org/10.1177/00185787261502968
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Recorded Urinary Ketone Results After Initiation of SGLT2 Inhibitors in Patients With and Without Diabetes: A Single-Center Retrospective Descriptive Study

Akinori Hayashi, Hiroshi Inano, Katsuya Otori, Makiko Iwasawa et al.
Hospital Pharmacy
Diabetes Treatment and Management
article

Recorded Urinary Ketone Results After Initiation of SGLT2 Inhibitors in Patients With and Without Diabetes: A Single-Center Retrospective Descriptive Study

Akinori Hayashi, Hiroshi Inano, Katsuya Otori, Makiko Iwasawa, Masahiro Kobayashi, Naoya Shimizu, Moeko Yasui, Ikumi Nagasaki
article en

Abstract

Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are prescribed for diabetes, chronic heart failure, and chronic kidney disease but are rarely associated with ketoacidosis, including euglycemic ketoacidosis. Although ketonuria is nonspecific and is not diagnostic of ketoacidosis, a positive urinary ketone result may prompt further clinical assessment. This study compared the proportion of participants with a recorded urinary ketone result after SGLT2i initiation between those with and without diabetes. Methods: This retrospective, single-center descriptive study included adults who initiated SGLT2i therapy at the study hospital between April 2022 and March 2023 and continued treatment for at least 180 days. Urinary ketone results, semiquantitative grades, and selected gastrointestinal symptoms documented in the electronic health record were assessed. Results: Among 465 participants, a urinary ketone result was recorded in 273 of 350 participants in the diabetes group (78.0%) and 65 of 115 participants in the non-diabetes group (56.5%) (odds ratio, 2.73; 95% confidence interval, 1.74-4.26). During follow-up, 27 participants had a positive urinary ketone result; the highest recorded grade was 2+ or higher in 17 (63.0%). Among 127 participants without a recorded urinary ketone result, selected gastrointestinal symptoms were documented in 11 (8.7%), and no blood ketone result was identified for these participants. No documented hospital admissions for ketoacidosis were identified in the study hospital records. Conclusions: The proportion of participants with a recorded urinary ketone result after SGLT2i initiation was lower in the non-diabetes group than in the diabetes group. Although urinary ketone positivity alone cannot confirm ketoacidosis, a positive semiquantitative result may prompt context-based clinical review and, when clinically indicated, confirmatory evaluation. These findings suggest the importance of maintaining awareness of SGLT2i-associated ketoacidosis, including euglycemic ketoacidosis, regardless of diabetes status, and a potential role for pharmacists in facilitating context-based ketone assessment when clinically indicated.

Hospital Pharmacy
Kitasato University Hospital (JP), Kitasato University (JP)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon